A.A. Novik, T.I. Ionova, S.A. Kalyadina
Quality of life and symptoms in postmenopausal women with hormone receptor positive advanced breast cancer undergoing treatment with Fazlodex
Quality of life treatment response and symptom treatment response in Faslodex was examined. 115 postmenopausal women (mean age - 58.1 (SD 9.4) with progression after prior antiestrogen therapy were included in this multicenter longitudinal study. For postmenopausal women with hormone - sensitive advanced breast cancer receiving Faslodex clinical benefit rate (complete response + partial response + stable disease >24 weeks) was 54.5% (at a median follow-up of 11 months) Quality of life treatment response (QoL improvement or QoL stabilization) was achieved in the majority of patients with hormone-positive advanced breast cancer receiving Faslodex.
Prolongation of Faslodex treatment in patients with hormone-positive advanced breast cancer is associated with decline of symptom severity, prevalence, and number of symptoms.